Want to see HK:7666 full AI Analyst Report?
Metis TechBio Co., Ltd. Class H (7666) AI Stock Analysis
Metis TechBio Co., Ltd. Class H
(HKEX:7666)
The score is held back primarily by persistent heavy losses and ongoing negative operating/free cash flow despite improved revenue and gross profitability, indicating continued reliance on external funding. Technicals are also bearish with price below key moving averages and negative MACD. Balance sheet repair (positive equity and much lower debt) is a meaningful offset but not enough to overcome profitability and momentum risks.
Metis TechBio Co., Ltd. Class H (7666) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 13.19B
- Dividend Yield
- ―
- Average Volume (3M)
- 7.36M
- Price to Earnings (P/E)
- -30.8
- Beta (1Y)
- -0.02
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 150
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Metis TechBio Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Metis TechBio Co., Ltd., founded in 2020 and headquartered in Beijing, China, (previously Hangzhou Jitai Pharmaceutical Technology Co., Ltd.) specializes in the advanced research and development of AI-powered nanomaterials. The company's core mission...
Metis TechBio Co., Ltd. Class H Financial Statement Overview
Summary
Financials show mixed progress. Revenue rebounded strongly in 2025 and gross margin improved substantially, while the balance sheet de-risked with positive equity and sharply reduced debt. Offsetting this, the company remains deeply loss-making with very large negative operating margins and continued negative operating/free cash flow, indicating ongoing funding dependence.
Income Statement
24NegativeBalance Sheet
46NeutralCash Flow
28Negative| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 14.63M | 206.76K | 1.32M |
| Gross Profit | 9.66M | -4.66M | -4.52M |
| EBITDA | -45.40M | -41.34M | -67.03M |
| Net Income | -54.59M | -69.65M | -82.32M |
Balance Sheet | |||
| Total Assets | 184.61M | 143.59M | 185.12M |
| Cash, Cash Equivalents and Short-Term Investments | 161.04M | 107.94M | 118.55M |
| Total Debt | 18.76M | 320.89M | 310.42M |
| Total Liabilities | 34.96M | 332.26M | 317.58M |
| Stockholders Equity | 148.93M | -189.31M | -137.79M |
Cash Flow | |||
| Free Cash Flow | -19.54M | -33.84M | -34.22M |
| Operating Cash Flow | -16.94M | -33.37M | -27.22M |
| Investing Cash Flow | 4.89M | 11.01M | -57.28M |
| Financing Cash Flow | 51.48M | 19.99M | 113.16M |
Metis TechBio Co., Ltd. Class H Peers Comparison
Overall Rating
HK:231569Neutral
HK:996652Neutral- HK:766647Neutral
HK:968846Neutral
HK:217139Underperform
HK:249339Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:2315 | 69Neutral | HKD 17.02B | 38.23 | 15.94% | ― | 48.04% | 166.72% |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:7666 | 47Neutral | HKD 13.19B | -30.77 | 270.37% | ― | ― | ― |
| HK:9688 | 46Neutral | HKD 21.69B | -12.70 | -27.40% | ― | 5.38% | 16.86% |
| HK:2171 | 39Underperform | HKD 6.32B | -56.08 | -9.45% | ― | 68.12% | 81.84% |
| HK:2493 | 39Underperform | HKD 13.86B | -6.55 | -179.83% | ― | 385.38% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:7666 | Metis TechBio Co., Ltd. Class H | 11.15 | -12.65 | -53.15% | |
| HK:9688 | Zai Lab Ltd | 17.37 | -3.65 | -17.36% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:2171 | CARsgen Therapeutics Holdings Ltd. | 10.63 | -6.92 | -39.43% | |
| HK:2315 | Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H | 38.30 | 9.06 | 30.98% | |
| HK:2493 | Mabwell (Shanghai) Bioscience Co., Ltd. Class H | 18.23 | -9.57 | -34.42% |
Metis TechBio Co., Ltd. Class H Corporate Events
Metis TechBio Narrows Losses as Biological AI Strategy Gains Momentum
Metis TechBio Co., Ltd. reported unaudited interim results for the first half of 2026, posting operating revenue of RMB154.3 million, a sharp increase from a low base a year earlier, and holding RMB3,025.3 million in cash, deposits and marketable fin...
Metis TechBio to Join Hang Seng Composite Index, Eyes Broader Investor Base
Metis TechBio Co., Ltd., a Hong Kong-listed joint stock company from the Chinese mainland, trades its H shares on the Main Board of the Stock Exchange of Hong Kong. Its listing gives the company exposure to both Hong Kong and mainland investors throu...
Metis TechBio Sets August Board Meeting to Review Interim Results and Dividend
Metis TechBio Co., Ltd. has scheduled a board meeting for August 25, 2026 to review and approve the unaudited interim results for the six months ended June 30, 2026. The board will also consider the declaration of an interim dividend and attend to ot...
Metis TechBio Strengthens Governance With New Joint Company Secretary and HKEX Waiver
Metis TechBio Co., Ltd. has appointed Nan Cao as joint company secretary effective 4 August 2026, alongside existing joint company secretary Hei Chan, in a move that strengthens its legal and governance capabilities. Cao brings a legal background in...
Metis TechBio to Deploy AI Formulation Platform at Hengrui Pharmaceuticals
Metis TechBio Co., Ltd., a Hong Kong-listed AI drug delivery specialist, has built its business around NanoForge, an AI-driven nano-delivery platform backed by the world’s largest proprietary lipid nanoparticle library. Leveraging this infrastr...
Metis TechBio Reshapes Finance and Governance Team After Hong Kong Listing
Metis TechBio Co., Ltd. announced that chief financial officer, board secretary, joint company secretary and Hong Kong process agent Dr. Chong Fu will step down from these roles effective August 1, 2026, transitioning to an advisory position focused...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 14, 2026